ESPR Share Price Performance
US$1.91
1.00 (110.51%)
7.3% overvalued intrinsic discount
US$1.78
Fair Value
Price US$1.91
AnalystLowTarget US$1.78
AnalystConsensusTarget US$6.50
AnalystHighTarget US$15.92
Fair ValueUS$1.78
Share Pricen/a
Esperion Therapeutics, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 36 Fair Values set on narratives written by author
ESPR Community Narratives
AN
Fair Value
·Fair Value US$1.78 7.3% overvalued intrinsic discount
Regulatory Pressures And Fierce Competition Will Compress Margins
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value US$6.5 70.6% undervalued intrinsic discount
Rising Digital Adoption And Global Partnerships Will Shape Future Markets
0users have liked this narrative
0users have commented on this narrative
18users have followed this narrative
AN
Fair Value
·Fair Value US$15.92 88.0% undervalued intrinsic discount
Aging Population And Precision Medicine Will Expand Cardiovascular Care
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Regulatory Pressures And Fierce Competition Will Compress Margins
Key Takeaways Increasing competition and regulatory scrutiny threaten profitability and growth prospects, as aggressive pricing controls and tighter approval standards limit margin expansion. Heavy dependence on a single drug platform exposes Esperion to significant risk from innovation by rivals and shifting therapeutic trends toward personalized medicine.Read more
AN
US$1.78
7.3% overvalued intrinsic discount
Fair Value
Profit Margin
19.79%
Future PE
8.92x
Price in 2029
US$2.19
Aging Population And Precision Medicine Will Expand Cardiovascular Care
Key Takeaways Surging uptake among statin-intolerant patients and strong international momentum suggest revenue growth and profitability could exceed current consensus expectations. Unique oral therapy positioning, innovative commercial execution, and operational flexibility provide a durable competitive edge and significant growth optionality.Read more
AN
US$15.92
88.0% undervalued intrinsic discount
Fair Value
Profit Margin
35.37%
Future PE
22.38x
Price in 2029
US$19.46
Rising Digital Adoption And Global Partnerships Will Shape Future Markets
Key Takeaways Growing adoption of cholesterol therapies, international partnerships, and improved patient access are expected to drive sustained revenue and margin growth. Extended patent protection and pipeline expansion reduce near-term risks and offer long-term growth opportunities through new treatment indications.Read more
AN
US$6.5
70.6% undervalued intrinsic discount
Fair Value
Profit Margin
27.23%
Future PE
15.29x
Price in 2029
US$7.94
Trending Discussion
Recently Updated Narratives
AN
ESPR: Vision 2040 Progress Will Likely Mask Corstasis Execution Risk
Fair Value: US$1.78 7.3% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
ESPR: Vision 2040 Execution And ESP-2001 Progress Will Drive Future Upside
Fair Value: US$15.92 88.0% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
ESPR: Overweight Rating And Accretive Deal Hunt Will Support Bullish Sentiment
Fair Value: US$6.5 70.6% undervalued intrinsic discount
18 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Esperion Therapeutics, Inc. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
May 07, 2026
- -0.088
- 56.08%
- -5.63%
- -180.6%
About ESPR
- Founded
- 2008
- Employees
- 294
- CEO
- WebsiteView website
Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company’s marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was formerly known as HDL Therapeutics, Inc. and changed its name to Esperion Therapeutics, Inc. in May 2008. The company was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
